

IRONWOOD PHARMACEUTICALS INC  
Form 8-K  
January 07, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report Pursuant to**  
**Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

January 7, 2019

**IRONWOOD PHARMACEUTICALS, INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction  
of incorporation)*

**001-34620**

*(Commission File Number)*

**04-3404176**

*(I.R.S. Employer  
Identification Number)*

**301 Binney Street**  
**Cambridge, Massachusetts**

*(Address of principal  
executive offices)*

**02142**

*(Zip code)*

**(617) 621-7722**

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

*(Registrant's telephone  
number,*

*including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02 Results of Operations and Financial Condition.**

Beginning on January 7, 2019, Ironwood Pharmaceuticals, Inc. (the Company) intends to use the presentation (the Ironwood Presentation) furnished herewith, or portions thereof, which provides updates on the Company's recent business activities and other strategic matters, in one or more meetings with or presentations to investors. The Ironwood Presentation contains information regarding the Company's results of operations for 2018. A copy of the Ironwood Presentation is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Ironwood Presentation is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

**Item 7.01 Regulation FD Disclosure.**

Beginning on January 7, 2019, the Company intends to use the presentation (the Cyclерion Presentation) and business summary (the Cyclерion Business Summary) furnished herewith, or portions thereof, which provide an overview of the proposed business of Cyclерion Therapeutics, Inc., in one or more meetings with or presentations to investors. Cyclерion Therapeutics, Inc. is expected to operate the Company's soluble guanylate cyclase business following the Company's planned separation into two independent, publicly traded companies. Copies of the Cyclерion Presentation and Cyclерion Business Summary are furnished as Exhibit 99.2 and Exhibit 99.3, respectively, and are incorporated herein by reference.

The Cyclерion Presentation and the Cyclерion Business Summary are being furnished pursuant to Item 7.01 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

*This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the Cyclерion's business following the separation. Each forward-looking statement is subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the possibility that the Company may not complete the separation on the terms or timeline currently contemplated, if at all, and the risks listed under the heading Risk Factors and elsewhere in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 6, 2018, and in the Company's subsequent SEC filings, including SEC filings related to the proposed separation. These forward-looking statements (except as otherwise noted) speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update these forward-looking statements.*

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Edgar Filing: IRONWOOD PHARMACEUTICALS INC - Form 8-K

Exhibit No.	Description
99.1	<u>Ironwood Presentation</u>
99.2	<u>Cyclerion Presentation</u>
99.3	<u>Cyclerion Business Summary</u>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Ironwood Pharmaceuticals, Inc.**

Dated: January 7, 2019

By: /s/ Gina Consylman  
Name: Gina Consylman  
Title: Senior Vice President, Chief Financial Officer

---